Sign inJoin waitlistJoin the waitlist

Dillon

Professor of Medicine, Medicine- Hematology and Oncology · University of Virginia

Credentials: · · ·

History

University of Virginia
Present

Research

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced…
Journal of Clinical Oncology · 2022 · 629 citations
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
JAMA Oncology · 2019 · 378 citations
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer
Journal of the National Cancer Institute · 2014 · 229 citations

CB
Christiana Brenin
8 papers
Trish Millard
7 papers · 1 as a fellow
Craig Slingluff
6 papers
Anne Mills
5 papers
IF
Ibrahim Fanous
5 papers · 1 as a resident
Paul Read
5 papers
Camilo Fadul
4 papers
Elizabeth Gaughan
4 papers
James Harrison
4 papers
Leslie Blackhall
4 papers
Norman Sharpless
4 papers
Ryan Gentzler
4 papers

Clinical trials

Focused Ultrasound and Gemcitabine in Breast Cancer
Principal investigator · Active not recruiting · Phase 1
Patrick Dillon, MD
2022–2030
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
Principal investigator · Withdrawn · Phase 2
University of Virginia
2019–2023
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
Principal investigator · Completed · Phase 1
University of Virginia
2019–2022
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
Principal investigator · Withdrawn · Early phase 1
University of Virginia
2018